Dapagliflozin improves CKD outcomes 'even without diabetes'
The drug has potential for people with renal disease in need of improved treatment options, investigators say
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
Use of dapagliflozin in patients with chronic kidney disease can improve outcomes in patients with and without type 2 diabetes, trial results show.
Results of the DAPA-CKD trial were presented to delegates at the European Society of Cardiology’s virtual congress (ESC 2020) this week.
More than 4300 participants were enrolled in the international trial, all with chronic kidney disease (CKD), having an estimated glomerular filtration